Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBIT (2016 - 2025)

Historic EBIT for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $34.3 million.

  • Amicus Therapeutics' EBIT rose 5822.06% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 52946.48%. This contributed to the annual value of $24.9 million for FY2024, which is 13221.82% up from last year.
  • As of Q3 2025, Amicus Therapeutics' EBIT stood at $34.3 million, which was up 5822.06% from -$9.5 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' EBIT registered a high of $34.3 million during Q3 2025, and its lowest value of -$75.3 million during Q1 2022.
  • For the 5-year period, Amicus Therapeutics' EBIT averaged around -$23.9 million, with its median value being -$27.7 million (2024).
  • In the last 5 years, Amicus Therapeutics' EBIT surged by 53258.4% in 2024 and then tumbled by 16329.93% in 2025.
  • Over the past 5 years, Amicus Therapeutics' EBIT (Quarter) stood at -$72.1 million in 2021, then soared by 41.33% to -$42.3 million in 2022, then surged by 91.28% to -$3.7 million in 2023, then soared by 532.58% to $16.0 million in 2024, then skyrocketed by 114.57% to $34.3 million in 2025.
  • Its EBIT was $34.3 million in Q3 2025, compared to -$9.5 million in Q2 2025 and -$8.0 million in Q1 2025.